Zobrazeno 1 - 10 of 27 pro vyhledávání: '"Leigh Marcus"'
1
Akademický článek
Cushing disease in a patient with multiple endocrine neoplasia type 2B
Autor: Kannan Kasturi, Lucas Fernandes, Martha Quezado, Mary Eid, Leigh Marcus, Prashant Chittiboina, Mark Rappaport, Constantine A. Stratakis, Brigitte Widemann, Maya Lodish
Publikováno v: Journal of Clinical and Translational Endocrinology Case Reports, Vol 4, Iss , Pp 1-4 (2017)
Context: Multiple endocrine neoplasia type 2B (MEN2B) is a rare autosomal-dominant cancer syndrome characterized in part by metastatic medullary thyroid cancer (MTC) and pheochromocytoma. Cushing disease is a rare cause of endogenous hypercortisolism
Externí odkaz: https://doaj.org/article/0eaa20c40e5549579e5072c8c9bfaaad
Zobrazit plný text záznamu
2
Data from Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
Autor: Frank M. Balis, Samuel A. Wells, Seth M. Steinberg, Eva Dombi, Maya Lodish, Maria J. Merino, Patricia O. Whitcomb, Alberta Aikin, Leigh Marcus, Meredith K. Chuk, Brigitte C. Widemann, Elizabeth Fox
Purpose: Medullary thyroid carcinoma (MTC) is a manifestation of multiple endocrine neoplasia type 2 (MEN2) syndromes caused by germline, activating mutations in the RET (REarranged during Transfection) proto-oncogene. Vandetanib, a VEGF and EGF rece
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044bad50076cee5828c0380bdf133ec6
https://doi.org/10.1158/1078-0432.c.6521100
Zobrazit plný text záznamu
4
Development of Tissue-Agnostic Treatments for Patients with Cancer
Autor: Steven Lemery, Lola Fashoyin-Aje, Leigh Marcus, Sandra Casak, Julie Schneider, Marc Theoret, Paul Kluetz, Richard Pazdur, Julia A. Beaver
Publikováno v: Annual Review of Cancer Biology. 6:147-165
In 2017 the FDA (US Food and Drug Administration) approved pembrolizumab, a programmed death 1 (PD-1) inhibitor, for the treatment of unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b63bd985c5b6552e0d295b307c6a8dc
https://doi.org/10.1146/annurev-cancerbio-060921-021828
Zobrazit plný text záznamu
6
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement
Autor: Timil H. Patel, Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Robert N. Schuck, Yangbing Li, Xinyuan Zhang, Jeanne Fourie Zirkelbach, Rosane Charlab, Jiang Liu, Yuching Yang, Steven J. Lemery, Richard Pazdur, Marc R. Theoret, Lola A. Fashoyin-Aje
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research.
On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ff235b94f6482a85e550b76940ca39
https://pubmed.ncbi.nlm.nih.gov/36206041
Zobrazit plný text záznamu
7
FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors
Autor: Hong Zhao, Whitney S. Helms, Richard Pazdur, Leigh Marcus, Martha Donoghue, Guoxiang Shen, Patricia Keegan, Stephanie Aungst, Olen Stephens, Claire E. Myers
Publikováno v: Clinical Cancer Research. 27:928-932
The FDA-approved entrectinib on August 15, 2019, for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b36e9090eaed93e7ab9bfbe7a0651bc
https://doi.org/10.1158/1078-0432.ccr-20-2771
Zobrazit plný text záznamu
9
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Autor: Leigh Marcus, Steven Lemery, Patricia Keegan, Richard Pazdur
Publikováno v: Clinical Cancer Research. 25:3753-3758
The FDA approved pembrolizumab on May 23, 2017, for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H), or mismatch repair deficient (dMMR) solid tumors that have progressed followin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb918343cdb45258e1fdd0ef2bdc2a9f
https://doi.org/10.1158/1078-0432.ccr-18-4070
Zobrazit plný text záznamu
10
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Autor: Kirsten B. Goldberg, Lola Fashoyin-Aje, William F. Pierce, Marc R. Theoret, Sirisha Mushti, Paul G. Kluetz, Richard Pazdur, Yuan Li Shen, Leah Her, Leigh Marcus, Sandra Casak, Steven Lemery, Joyce Cheng
Publikováno v: Clin Cancer Res
The FDA approved pembrolizumab on June 29, 2020, for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) colorectal cancer with no prior systemic treatment for advanced disease. The approval was based on
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::363be90aa542b7139583b6586788a137
https://pubmed.ncbi.nlm.nih.gov/33846198
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje